Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance

about

Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance

Item

http://www.wikidata.org/entity/Q59137067

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@en

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@nl

type

Item

label

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@en

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@nl

prefLabel

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@en

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@nl

P1476

Subcutaneous Interferon-β1a Do ...... nd Post-Marketing Surveillance

@en

P2093

Alan Gillett

http://www.w3.org/2001/XMLSchema#string

Brooke Hayward

http://www.w3.org/2001/XMLSchema#string

Julie Aldridge

http://www.w3.org/2001/XMLSchema#string

Meritxell Sabidó

http://www.w3.org/2001/XMLSchema#string

Saritha Venkatesh

http://www.w3.org/2001/XMLSchema#string

P2860

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

Monitoring product safety in the postmarketing environment.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.

Aspirin and multiple sclerosis

The Incidence, Prevalence, and Mortality of Stroke in France, Germany, Italy, Spain, the UK, and the US: A Literature Review

P2888

s12325-018-0790-1

P304

2041-2053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-018-0790-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30255416

http://www.w3.org/2001/XMLSchema#string

P932

6224000

http://www.w3.org/2001/XMLSchema#string